Table 1.

Patient characteristics.

Variables	n = 260	Variables	n = 260
Age	64.0 (18.0)	Tumor number
Gender (male (%))	192 (73.8)	Multiple (%)	183 (70.4)
BMI (kg/m2)	24.15 (4.9)	Lobe
TACE session	4 (5)	Right (%)	78 (30.0)
DM (yes(%))	77 (29.6)	Left (%)	23 (8.8)
ESRD (yes(%))	11 (4.2)	Bilobar (%)	159 (61.2)
Comorbidity (yes(%))	138 (53.1)	ALBI grade
Platelet count (x 1000/uL)	129.5 (106.25)	1 (%)	94 (36.3)
Bilirubin (mg/dL)	0.8 (0.5)	2 (%)	148 (57.1)
AST (U/L)	50.0 (47.0)	3 (%)	17 (6.6)
Albumin (g/dL)	3.7 ± 0.6	Child-Pugh classification
PT INR	1.2 (0.1)	A (%)	221 (86.3)
ICG-15 (%)	12.73 ± 16.52 (0- 29.25)	B (%)	32 (12.5)
Cr (mg/dL)	0.79 (0.35)	C (%)	3 (1.2)
AFP (ng/mL)	43.4 (649.7)	BCLC
Cirrhosis (yes(%))	170 (65.4)	0 (%)	8 (3.1)
Ascites (yes(%))	36 (13.8)	A (%)	53 (20.4)
HBV (yes(%))	141 (54.2)	B (%)	78 (30.0)
HCV (yes(%))	110 (42.3)	C (%)	111 (42.7)
Sarcopenia (yes(%))	130 (50.0)	D (%)	10 (3.8)
Maximal tumor diameter(cm)	3.3 (4.1)	HAP score
Portal vein thrombosis (yes(%))	28 (10.8)	A (%)	69 (27.8)
VP 1 and VP2 (yes(%))	13 (5.3)	B (%)	88 (35.5)
VP3 and VP4 (yes(%))	15 (5.8)	C (%)	66 (26.6)
AJCC stage		D (%)	25 (10.1)
I/II (%)	184 (70.8)	ART score
III (%)	76 (29.2)	0-1.5 points	146 (62.4)
		>2.5 points	88 (37.6)

AFP, alpha-fetoprotein; ALBI grade, albumin-bilirubin grade; AST, aspartate aminotransferase; ART score, Assessment for Retreatment with Transarterial Chemoembolization score; BCLC, Barcelona Clinic Liver Cancer; BMI, body mass index; DM, diabetes mellitus; ESRD, end-stage renal disease; HAP score, hepatoma arterial-embolization prognostic score; HBV, hepatitis B virus infection; HCV, hepatitis C virus infection; ICG-15, indocyanine green retention at 15 minutes; INR, international normalized ratio; PT, prothrombin time.